GlassScriptPhysician profile
Veronica D Crawley
NPI 1922366442
$14,673.33
in general payments reported to CMS, 2019-2025
66 companies · $2,932 in 2025
The $2,932 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,486 · 2022: $3,007 · 2023: $3,214 · 2024: $3,034 · 2025: $2,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,116 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,116.02 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,566.66 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,659.82 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,396.71 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $1,227.14 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $997.17 | 2021-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $844.52 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $594.99 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $570.02 | 2021-2025 | Jardiance, Synjardy, Ofev |
| Janssen Pharmaceuticals, INC | $392.58 | 2021-2025 | Spravato |
| Astellas Pharma US INC | $352.92 | 2021-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $282.64 | 2021-2025 | Rexulti, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $260.82 | 2021-2024 | |
| Esperion Therapeutics, INC. | $228.61 | 2021-2025 | Nexletol |
| Dexcom, INC. | $223.87 | 2021-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $196.00 | 2023-2025 | Cologuard Collection Kit |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Crawley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.